Tourmaline Bio, Inc.
TRML · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | – | – | 50% | – |
| R&D Expenses | $20 | $20 | $21 | $19 |
| G&A Expenses | $6 | $6 | $5 | $5 |
| SG&A Expenses | $6 | $6 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26 | $26 | $26 | $24 |
| Operating Income | -$26 | -$26 | -$26 | -$24 |
| % Margin | – | – | -64,515% | – |
| Other Income/Exp. Net | $3 | $3 | $4 | $4 |
| Pre-Tax Income | -$23 | -$23 | -$22 | -$20 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$23 | -$23 | -$22 | -$20 |
| % Margin | – | – | -55,587.5% | – |
| EPS | -0.9 | -0.89 | -0.86 | -0.78 |
| % Growth | -1.1% | -3.5% | -10.3% | – |
| EPS Diluted | -0.9 | -0.89 | -0.86 | -0.78 |
| Weighted Avg Shares Out | 26 | 26 | 26 | 26 |
| Weighted Avg Shares Out Dil | 26 | 26 | 26 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $4 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$26 | -$23 | -$22 | -$24 |
| % Margin | – | – | -55,565% | – |